Cancer

Mustang Bio stock surged over 180% on Monday after the FDA granted its brain cancer drug candidate an orphan drug designation.

Julian McMahon, star of Charmed and Nip/Tuck, has died aged 56 following a private cancer battle. Read about his cause of death, family tributes, and his touching last message to daughter Madison.

A major Swedish study has linked tattoos to a 21% rise in lymphoma risk. Experts say it's time to rethink tattoo safety and push for stronger ink regulations. Learn what it means for your health.

Billionaire investor Steve Cohen invested over $100 million in two biopharma stocks, one of which has rallied over 90% in the past one month.

A new AI tool, FaceAge, analyses selfies to estimate biological age, which, according to a recent study, is a stronger indicator of cancer survival than actual age.

The wrestler's story highlights the importance of early detection and daily sunscreen use for all men's health.

Poprock legend Michael Bolton, 72, recently opened up about his cancer diagnosis and what his symptoms were— but what is glioblastoma, the disease killing 10k Americans yearly?

A mother of two, Laura McPherson, deceived her wealthy partner into giving her over £24,000 by falsely claiming she had terminal cancer.

Arizona patient dies after contracting donor's lung cancer, exposing rare transplant risks and screening challenges.

Recent studies show scented candles may emit harmful substances that can lead to respiratory problems and cognitive decline.

Treatment typically begins with neurosurgery. Complete tumour removal is crucial, as total resection provides significantly better survival

A new AI system detects 13 cancers with near-perfect accuracy, raising hopes for earlier diagnoses and better treatment options.

Australian cancer expert fights back and survives aggressive brain tumour with his own experimental treatment, offering hope for future patients.

The study also highlights how mental health issues can even force young adults into lower-paid jobs or unemployment.

Breast cancer is the most common form of cancer.

The UK government has awarded medtech funding to eight UK medtech companies which are developing pathbreaking tests and AI detection tools for faster treatment of life-threatening diseases, reducing the burden of NHS.

Cancer remains one of the most formidable health challenges worldwide.

A team of researchers have named almost 1000 chemicals, found in food and beauty products, that increase the risk of breast cancer.

The study, led by Dr Trey Ideker, a professor in the Department of Medicine at UC San Diego School of Medicine, showcases the potential of artificial intelligence in unravelling the complexities of cancer drug responses.

The experiment was carried out on lab-grown cells and mice.

With its AI-powered technology, the company has developed a groundbreaking solution for identifying optimal drug treatments for individual dogs and cats with blood cancers.

Absci, a drug and target discovery company, has been harnessing the power of deep learning AI to develop new and existing disease treatments.

The UK government has chalked out a long-term plan to use AI to develop treatments for diseases with higher death rates through the AI Life Sciences Accelerator Mission.

The new therapy, known as glofitamab or Columvi®, has been approved by both the Medicines and Healthcare Products Regulatory Agency (MHRA) and the National Institute of Health and Care Excellence (NICE).

University of Rochester scientists successfully transfer genes leading to improved health and extended lifespan in mice, potentially unlocking secrets of ageing and lifespan enhancement in humans.

The World Health Organisation has added over 500 lifesaving essential medicines to its essential list including the first approvals for multiple sclerosis.

The projected trajectory indicates that by 2025, more women will be diagnosed with lung cancer than men in the UK. Historically, lung cancer has been predominantly associated with male smokers.

Loss of the Y chromosome has been linked to an increased risk of developing various cancers, with findings shedding light on the intricate relationship between ageing, genetics and cancer progression.

Of people that have been diagnosed with iCCA at an early stage, 24 per cent are still alive five years after diagnosis.

The new study funded by top US research organisations like the National Institutes of Health, Harvard Cancer Center Ovarian Cancer SPORE, Dana Farber Cancer Institute and others reveals that mutations in the BRCA1 and BRCA2 genes associated with breast and ovarian cancer can be detected without sequencing.